Le Lézard
Classified in: Health
Subject: TRI

Patented Antibody Brings Professor's Research Closer to Helping Diabetics


CEDARVILLE, Ohio, May 9, 2018 /PRNewswire-USNewswire/ -- Amid lectures and grading papers, one professor has helped engineer and test an antibody that has potential to treat the results of a multitude of vascular conditions, including pain in walking and limb necrosis associated with late-stage diabetes.  

Located in southwest Ohio, Cedarville University is an accredited, Christ-centered, Baptist institution with an enrollment of 3,963 undergraduate, graduate, and online students in more than 150 areas of study. Founded in 1887, Cedarville is recognized nationally for its authentic Christian community, rigorous academic programs, strong graduation and retention rates, accredited professional and health science offerings, and leading student satisfaction ratings. For more information about the University, visit www.cedarville.edu.

Dr. Rocco Rotello, associate professor of pharmaceutical sciences at Cedarville University, has secured a patent for his seven-year antibody research and is steadily approaching a treatment for a multitude of vascular conditions.

The object of Rotello's patented research is an engineered antibody. Antibodies are proteins that act as keys that fit biological locks on certain cells to initiate a process within the cell. Rotello's antibody is designed for compatibility with endothelial cells.

Endothelial cells form the interior walls of blood vessels (arteries, veins and capillaries), the passageways for blood to and from the heart. When endothelial cells are healthy, they ensure blood flows correctly by keeping the vessel walls strong and stable. If the cells are unhealthy, the vessel walls may leak, which can lead to a host of issues, including irregular blood pressure, clotting and edema.  

Rotello's patented antibody flips the switch that sends endothelial cells into survival mode, which strengthens the walls of blood vessels. As a result, the antibody, which is injected into a subject, has the potential to treat numerous vascular conditions.

While various treatments currently exist for improving blood flow in the heart, such as stents, Rotello's antibody will be the first of its kind to promote blood flow to the limbs, hands and feet. The goal is to alleviate debilitating pain, limb death and amputation that would otherwise occur.  

Rotello expects that human drug trials will begin in late 2019 and a final treatment may be widely available by 2023.

Located in southwest Ohio, Cedarville University is an accredited, Christ-centered, Baptist institution with an enrollment of 3,963 undergraduate, graduate, and online students in more than 150 areas of study. Founded in 1887, Cedarville is recognized nationally for its authentic Christian community, rigorous academic programs, strong graduation and retention rates, accredited professional and health science offerings, and leading student satisfaction ratings. For more information about the University, visit www.cedarville.edu.

SOURCE Cedarville University


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: